Should AbbVie Inc. Or Gilead Sciences Buy These Tiny Biotech Stocks?

January 14, 2015 2:44 AM

15 0

Recently approved new drugs from AbbVie (NYSE: ABBV ) and Gilead Sciences (NASDAQ: GILD ) means that the two biotech titans are locked in a heated battle for hepatitis C market share, but these companies may be better served shifting their attention away from this tussle toward the next generation of hepatitis C drugs making their way through drug pipelines at Achillion Pharmaceuticals (NASDAQ: ACHN ) and Regulus Therapeutics (NASDAQ: RGLS ) .

Dominating disordersThere's little question that Gilead Sciences' and AbbVie's success stems from a proven ability to launch revolutionary drugs that redefine their markets.

Read more

To category page